Editas Medicine’s Post

👉 Watch the video to learn how Hugo Gagnon, Chief Science Officer and President at PhenoSwitch Bioscience delves into the groundbreaking world of high-throughput #proteomics, paving the way for safer and more efficient gene therapy products. Discover how #ZenoSWATH #DIA technology empowers us to explore the complex cellular networks like never before. Don't miss this extraordinary science! #DrugDiscovery #ExtraordinaryScience #ZenoTOF #MassSpectrometry

Discover how to overcome scale-up challenges for cell and gene therapy manufacturing development. As demand for cell and gene therapies grows, so does the need to secure an efficient supply chain and improved operational efficiencies.    Watch to learn steps that every #biomanufacturer can take to mitigate raw material shortages and how to overcome scale-up challenges many in the industry face. #AvantorSetsScienceInMotion

It may be summer, but it’s still bone-chillingly cold in our liquid nitrogen cryopreservation tanks. The tanks’ typical temperature is -150 degrees Celsius – around ten degrees colder than the average temperature on Saturn, which is almost un-brrr-lievable!          Along with OmniaBio, we think we’re pretty cool for specializing in developing customized #cryopreservation processes for cell and gene therapy products. You snowe it to yourself to read more about our expertise in the “CDMO Education Centre” blog post:           Follow #CDMOTIPS for more cold, hard facts about developing and manufacturing cell and gene therapies. 

A focused issue on a hot nanomedicine area.

Base editing is a form of gene editing that converts one nucleotide base into another without cutting both strands of DNA. Our base editing systems include A base editors for 𝘪𝘯 𝘷𝘪𝘷𝘰 gene editing therapeutics and C base editors for 𝘦𝘹 𝘷𝘪𝘷𝘰 applications for gene knock-outs in cell therapies. Explore how Life Edit can support your gene editing needs at lifeeditinc.com/platforms. #BaseEditing #GenomeEditing

ICYMI: 7 questions gene therapy developers should ask their CDMO (and what they will ask you!) is now on demand 💻. Watch this informative webinar where our gene therapy experts answered critical questions around yield, commercial readiness, validated scale-down models, automation of analytical assays, and much more ➡️https://hubs.li/Q02m0FBC0

Alex Templar, Senior Business Development Manager at the Cell and Gene Therapy Catapult, talking at Informa Connect's Cell and Gene Therapy #Manufacturing and #Commercialisation Europe event in #Dublin today! We gave two talks today delving into how you can #accelerate your in-house GMP manufacturing capabilities, and how you can use #ProcessAnalyticalTechnologies to develop closed, automated and adaptable processes. Learn more about how we can support your #ATMP manufacturing development: https://buff.ly/3FdtV1S #CellTherapies #GeneTherapies #AdvancedTherapies

With ISCT, International Society for Cell & Gene Therapy's annual meeting starting tomorrow, the Cell and Gene team at TTP is looking forward to discussing cutting-edge research in a global community. In anticipation of ISCT, our previous podcast: 'Cell and Gene: How to make advanced therapies accessible' explores the potential power of Cell and Gene therapies and how to scale the manufacture of living drugs. Professor Jacob Petersen, comments on the podcast: "I have a nine-year-old daughter that five years ago got type one diabetes. I have been working with type one diabetes at Novo Nordisk for several decades, trying to come up with new treatment modalities for type one diabetes. And I thought I knew it all. I knew all the KJOLs and all the doctors. And I had a deep insight into the disease myself. When she was diagnosed, I just said, okay, how hard can it be to inject insulin a few times a day? But it was a life-changing experience. It is a chronic disease that is 24/7. You cannot say today, I don't want to be a diabetic, because then you may not be there in the morning." Listen now: https://bit.ly/43cmzpL #ISCT2023 #CellandGene #MedicalInnovation